171 related articles for article (PubMed ID: 17708308)
1. Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma.
Gao ZL; Zhang C; Du GY; Lu ZJ
Hepatogastroenterology; 2007; 54(77):1591-5. PubMed ID: 17708308
[TBL] [Abstract][Full Text] [Related]
2. The combination assay with circulating vascular endothelial growth factor (VEGF)-C, matrix metalloproteinase-9, and VEGF for diagnosing lymph node metastasis in patients with non-small cell lung cancer.
Tamura M; Oda M; Matsumoto I; Tsunezuka Y; Kawakami K; Ohta Y; Watanabe G
Ann Surg Oncol; 2004 Oct; 11(10):928-33. PubMed ID: 15383417
[TBL] [Abstract][Full Text] [Related]
3. Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.
Wu CY; Wu MS; Chiang EP; Chen YJ; Chen CJ; Chi NH; Shih YT; Chen GH; Lin JT
Clin Cancer Res; 2007 Apr; 13(7):2054-60. PubMed ID: 17404086
[TBL] [Abstract][Full Text] [Related]
4. Elevated levels of serum and plasma metalloproteinases in patients with gastric cancer.
Endo K; Maehara Y; Baba H; Yamamoto M; Tomisaki S; Watanabe A; Kakeji Y; Sugimachi K
Anticancer Res; 1997; 17(3C):2253-8. PubMed ID: 9216697
[TBL] [Abstract][Full Text] [Related]
5. [Detection of serum levels of MMP-9 and VEGF in patients with bladder cancer].
Guan KP; Hou SK; Yan Z; Ye HY
Zhonghua Wai Ke Za Zhi; 2003 Jun; 41(6):430-2. PubMed ID: 12895351
[TBL] [Abstract][Full Text] [Related]
6. MMP-2, MMP-9, VEGF and CA 15.3 in breast cancer.
Quaranta M; Daniele A; Coviello M; Venneri MT; Abbate I; Caringella ME; Di Tardo S; Divella R; Trerotoli P; Di Gennaro M; Schittulli F; Fransvea E; Giannelli G
Anticancer Res; 2007; 27(5B):3593-600. PubMed ID: 17972522
[TBL] [Abstract][Full Text] [Related]
7. [Expressions of receptor-binding cancer antigen expressed on SiSo cells, vascular endothelial growth factor, and matrix metalloproteinase-9 in cervical carcinoma and correlation thereof with the invasion and metastasis of the cancerous tissues].
Liu R; Pu DM; Cheng YX; Yin L
Zhonghua Yi Xue Za Zhi; 2007 May; 87(19):1326-9. PubMed ID: 17727777
[TBL] [Abstract][Full Text] [Related]
8. High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer.
Vidal O; Metges JP; Elizalde I; Valentíni M; Volant A; Molina R; Castells A; Pera M
Br J Surg; 2009 Dec; 96(12):1443-51. PubMed ID: 19918848
[TBL] [Abstract][Full Text] [Related]
9. Circulating stromal cell derived factor-1alpha (SDF-1alpha) is predictive of distant metastasis in gastric carcinoma.
Woo IS; Hong SH; Byun JH; Kang JH; Jeon HM; Choi MG
Cancer Invest; 2008; 26(3):256-61. PubMed ID: 18317966
[TBL] [Abstract][Full Text] [Related]
10. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
11. [Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer].
Zhao J; Liu XY; Zhang QY; Jiang W
Zhonghua Zhong Liu Za Zhi; 2005 Nov; 27(11):676-9. PubMed ID: 16438890
[TBL] [Abstract][Full Text] [Related]
12. Expression of cyclooxygenase-2 and matrix metalloproteinase-9 in gastric carcinoma and its correlation with angiogenesis.
Sun WH; Sun YL; Fang RN; Shao Y; Xu HC; Xue QP; Ding GX; Cheng YL
Jpn J Clin Oncol; 2005 Dec; 35(12):707-13. PubMed ID: 16314343
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma.
Tseng CS; Lo HW; Chen PH; Chuang WL; Juan CC; Ker CG
Hepatogastroenterology; 2004; 51(59):1454-8. PubMed ID: 15362775
[TBL] [Abstract][Full Text] [Related]
14. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
[TBL] [Abstract][Full Text] [Related]
15. [Expressions of TGIF, MMP9 and VEGF proteins and their clinicopathological relationship in gastric cancer].
Hu ZL; Wen JF; Shen M; Liu Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 31(1):70-4. PubMed ID: 16562680
[TBL] [Abstract][Full Text] [Related]
16. [Preliminary results regarding vascular endothelial growth factor (VEGF-A) levels in the serum of gastric cancer patients].
Hălmaciu I; Gurzu S; Dobreanu M; Suciu BA; Brînzaniuc K
Rev Med Chir Soc Med Nat Iasi; 2012; 116(2):446-51. PubMed ID: 23077935
[TBL] [Abstract][Full Text] [Related]
17. Significance of VEGF and microvascular density in gastric carcinoma.
Kösem M; Tuncer I; Kotan C; Ibiloğlu I; Oztürk M; Türkdoğan MK
Hepatogastroenterology; 2009; 56(93):1236-40. PubMed ID: 19760978
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC).
Laack E; Scheffler A; Burkholder I; Boeters I; Andritzky B; Schuch G; Görn M; Vohwinkel G; Edler L; Fiedler W; Hossfeld DK
Lung Cancer; 2005 Oct; 50(1):51-8. PubMed ID: 15992959
[TBL] [Abstract][Full Text] [Related]
19. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer.
Hrabec E; Strek M; Nowak D; Hrabec Z
Respir Med; 2001 Jan; 95(1):1-4. PubMed ID: 11207010
[TBL] [Abstract][Full Text] [Related]
20. [The serum concentration of metalloproteinase 9 and 2 in non-small cell lung cancer patients].
Kopczyńska E; Dancewicz M; Kowalewski J; Kardymowicz H; Tyrakowski T
Pol Merkur Lekarski; 2007 Jun; 22(132):539-41. PubMed ID: 17874625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
